Valuation: Lundbeck

Market Cap 39.9B 6.11B 5.34B 4.94B 4.53B 8.57B 588B 8.72B 58.87B 23.13B 287B 22.93B 22.43B 992B P/E 2026 *
9.04x
P/E 2027 * 9x
Enterprise Value 43.99B 6.73B 5.88B 5.44B 4.99B 9.45B 649B 9.62B 64.9B 25.5B 317B 25.28B 24.73B 1,094B EV / Sales 2026 *
1.71x
EV / Sales 2027 * 1.54x
Free-Float
30.76%
Yield 2026 *
3.63%
Yield 2027 * 3.72%
1 day-0.42%
1 week-0.82%
Current month-0.55%
1 month-0.41%
3 months+4.45%
6 months-4.96%
Current year+0.55%
1 week 35.75
Extreme 35.75
36.65
1 month 35.65
Extreme 35.65
37.75
Current year 31.4
Extreme 31.4
39.9
1 year 28.5
Extreme 28.5
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%-0.82% - - 6.11B
+5.65%+6.12%+17.54%+104.37% 93.23B
+1.68%-2.16%+41.97%+144.70% 52.68B
+0.34%+5.00%+7.30%+281.82% 23.59B
+1.01%+5.45%-10.32%-19.20% 8.34B
+1.69%+10.47%-21.24%-28.77% 8.14B
+2.06%+3.67%-4.86%-24.05% 6.95B
+1.38%+2.55%+0.28%+24.31% 5.39B
+1.36%+4.39%-3.15%-3.62% 3.8B
+0.86%+1.85%+16.72%+21.29% 3.51B
Average +1.49%+2.27%+4.92%+55.65% 22.85B
Weighted average by Cap. +3.16%-0.97%+18.35%+114.92%

Financials

2026 *2027 *
Net sales 25.79B 3.95B 3.45B 3.19B 2.93B 5.54B 380B 5.64B 38.05B 14.95B 186B 14.82B 14.5B 641B 25.87B 3.96B 3.46B 3.2B 2.94B 5.56B 381B 5.65B 38.16B 14.99B 186B 14.87B 14.54B 643B
Net income 4.55B 697M 609M 563M 517M 978M 67.14B 995M 6.72B 2.64B 32.79B 2.62B 2.56B 113B 4.6B 703M 615M 569M 522M 988M 67.79B 1B 6.78B 2.66B 33.1B 2.64B 2.58B 114B
Net Debt 4.09B 626M 547M 506M 464M 878M 60.29B 894M 6.03B 2.37B 29.44B 2.35B 2.3B 102B -44.13M -6.75M -5.9M -5.46M -5.01M -9.48M -651M -9.65M -65.11M -25.58M -318M -25.37M -24.81M -1.1B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
16/07/26 DKK 36.40 +0.83% 29,871
15/07/26 DKK 36.10 +0.70% 39,430
14/07/26 DKK 35.85 -1.38% 52,796
13/07/26 DKK 36.35 +0.14% 67,337
10/07/26 DKK 36.30 0.00% 70,570
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
41.30DKK
Average target price
47.62DKK
Spread / Average Target
+15.31%

Quarterly revenue - Rate of surprise